Nendouvhada, Livhuwani Portia2025-01-172025-01-172024https://hdl.handle.net/10566/19823Metabolic dysfunction-associated liver disease (MASLD) occurs due to an excessive accumulation of fat in the liver (steatosis), independent of secondary causes such as excessive alcohol consumption, viral hepatitis, or certain medications. MASLD is a common chronic liver disease that can lead to end-stage liver disease eventually requiring a liver transplant. It is associated with metabolic syndrome (MetS), especially obesity, diabetes, hyperlipidemia, and hypertriglyceridemia. MASLD can advance to metabolic dysfunction-associated steatohepatitis (MASH), which causes inflammation and damage leading to scarring of the liver (cirrhosis). Only 43-44% of patients with steatosis progress to MASH, with 7-30% of MASH patients progressing to cirrhosis. To date, the mechanism of MASLD and its progression is not well understood, and there are no therapeutic strategies that are specifically tailored for MASLD/ MASH. The anti-obesity and anti-diabetic pharmacological approaches currently used were shown to reduce the MASLD progression, although they remain ineffective to completely treat or reverse its progression.enFas cell surface death receptorGold nanoparticlesGreen nanotechnologyMetabolic Dysfunction-Associated SteatohepatitisMetabolic Dysfunction-Associated Steatotic Liver DiseaseThesis